"Vincristine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
Descriptor ID |
D014750
|
MeSH Number(s) |
D03.132.436.681.827.817 D03.633.100.473.402.681.827.817
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Vincristine".
Below are MeSH descriptors whose meaning is more specific than "Vincristine".
This graph shows the total number of publications written about "Vincristine" by people in this website by year, and whether "Vincristine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 1 | 0 | 1 |
2003 | 0 | 1 | 1 |
2004 | 0 | 1 | 1 |
2007 | 0 | 2 | 2 |
2008 | 0 | 3 | 3 |
2010 | 0 | 2 | 2 |
2011 | 0 | 1 | 1 |
2012 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2015 | 0 | 1 | 1 |
2017 | 0 | 6 | 6 |
2019 | 1 | 0 | 1 |
2020 | 0 | 4 | 4 |
2021 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vincristine" by people in Profiles.
-
Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era. Int J Cardiol. 2021 Sep 15; 339:146-149.
-
Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine. Clin Transl Sci. 2021 07; 14(4):1490-1504.
-
Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis). BMC Cancer. 2021 Apr 06; 21(1):358.
-
Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. Leuk Lymphoma. 2021 08; 62(8):1869-1876.
-
Impact of Omission/Reduction of Vincristine From R-CHOP in Treatment of DLBCL. Clin Lymphoma Myeloma Leuk. 2021 03; 21(3):162-169.
-
MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era. Leuk Res. 2020 10; 97:106426.
-
Perspectives on chemotherapy for the management of double-hit lymphoma. Expert Opin Pharmacother. 2020 Apr; 21(6):653-661.
-
Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study. Int J Hematol. 2020 Apr; 111(4):567-573.
-
Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2). Support Care Cancer. 2020 Feb; 28(2):571-579.
-
Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance. Ann Hematol. 2018 Feb; 97(2):289-297.